Voyager Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Voyager Therapeutics, Inc. (VYGR) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$5.11 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-14.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-14
- Voyager Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$16.67M.
- Voyager Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$18.10M.
- Voyager Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was -$26.87M.
- Voyager Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-09-30 was -$3.52M.
- Voyager Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$5.11M, a 195.86% decline from fiscal 2016.
- Voyager Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $5.33M, a 78.03% decline from fiscal 2015.
- Voyager Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $24.27M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$16.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$34.77M derived: sum of 2 quarters · filed 2018-03-14 | -$5.11M 10-K · filed 2018-03-14 | |
| 2017-09-30 | -$18.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $11.56M 10-Q · filed 2017-11-02 | ||
| 2017-06-30 | $29.66M 10-Q · filed 2017-08-08 | |||
| 2016-12-31 | -$26.87M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$30.39M derived: sum of 2 quarters · filed 2018-03-14 | $5.33M 10-K · filed 2018-03-14 | |
| 2016-09-30 | -$3.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $32.20M 10-Q · filed 2017-11-02 | ||
| 2016-06-30 | $35.72M 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | $24.27M 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |